Klinikum Dortmund gGmbH

Dortmund 44145

3 studies enrolling now · 12 studies all time

What they study most

Advanced Cholangiocarcinoma, Arterial Thrombosis, Breast Cancer, Bronchiectasis, Cerebral Stroke, FGFR2 Gene Mutation, HER2-Positive Primary Breast Cancer, HIV Infection, HIV Infections, Ischemic Stroke; Ischemic Attack, Transient, Kidney Disease, Chronic, Perioperative Bleeding

Studies at this site

• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects — Recruiting now
• The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis — Recruiting now
• EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) — Recruiting now
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) — Running, not enrolling
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling
• Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis — Completed
• CERENOVUS Neurothrombectomy Devices Registry — Completed
• PeriOperative ISchemic Evaluation-3 Trial — Completed
• Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations — Stopped early
• Strategic Timing of Antiretroviral Treatment — Completed
• Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection — Stopped early